Please login to the form below

Not currently logged in

Concept Life Sciences adds to its scientific and commercial team

Dr Calvert and Dr Donaldson join the company to support growth

Michael DonaldsonConcept Life Sciences has appointed Dr Michael Donaldson (pictured right) as its principal scientist in its dermal department, a role that will see him take responsibility for its dermatology services.

With over 17 years’ experience in the pharmaceutical industry, Dr Donaldson was most recently director of biology in dermatology therapy area at GlaxoSmithKline.

Also joining the company is Dr Tim Calvert (pictured left), who becomes its vice president of business development, integrated discovery services, Europe.

Dr Calvert has experience in the delivery of integrated drug discovery and development solutions, supporting organisations ranging from virtual companies to global pharma.

Tim CalvertHe joins Concept from Aptuit, where he held various roles including senior director of integrated drug development, a role that saw him execute drug development programmes.

Philip Payne, chief commercial officer of Concept Life Sciences, said: “We are delighted to welcome both Tim and Michael to Concept.

“Their notable scientific and commercial backgrounds will be invaluable in supporting the continued expansion of the group.”

1st March 2018

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company Conferences, Events and Exhibition Stands is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...